kann man hier gar nicht verlieren.
krebs, grippe, hiv, ...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
Preliminary Data Shows Electroporation-Delivered DNA Vaccine Induces Significant Antigen-Specific T-cell and Antibody Responses in First, Low Dose Cohort
SAN DIEGO--(BUSINESS WIRE)--Oct. 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. Dr. David B. Weiner, Professor, University of Pennsylvania and Chairman of Inovio’s Scientific Advisory Board, presented the data at the Vaccine 3rd Global Congress in Singapore in a presentation entitled, “Delivering on the Promise of DNA Vaccines for HIV and Cancer: From Bench to Clinical Data.”
ir.inovio.com/...rol-newsArticle&ID=1338143&highlight=